NASDAQ:PCVX

Vaxcyte - PCVX News Today

$37.70

-0.18 (-0.48%)

(As of 03/24/2023 01:45 PM ET)

Add

Compare

Today's Range: $37.35
▼
$37.95
50-Day Range: $37.08
▼
$46.89
52-Week Range: $17.44
▼
$49.31

Volume: 155,175 shs
Average Volume: 659,038 shs
Market Capitalization: $3.02 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $64.83

Institutional Ownership

Get Vaxcyte News Delivered to You Automatically

PCVX Media Mentions By Week

PCVX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PCVX
News Sentiment
▼
0.58

0.35
▲
Average
Medical
News Sentiment

PCVX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PCVX Articles
This Week
▼
0

1
▲
PCVX Articles
Average Week

Source

Source	Headline
	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript finance.yahoo.com - March 13 at 4:55 AM
	Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update finanznachrichten.de - March 1 at 8:25 AM
	Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update finance.yahoo.com - March 1 at 8:25 AM
	Vaxcyte GAAP EPS of -$3.44 misses by $0.11 msn.com - March 1 at 8:25 AM
	Needham Keeps Their Buy Rating on Vaxcyte (PCVX) markets.businessinsider.com - March 1 at 8:25 AM
	Preview: Vaxcyte's Earnings benzinga.com - February 24 at 4:00 PM
	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants finance.yahoo.com - February 21 at 11:08 AM
	Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 finance.yahoo.com - February 16 at 7:22 PM
	Vaxcyte to Present at the SVB Securities Global Biopharma Conference finance.yahoo.com - February 7 at 8:49 PM
	Vaxcyte: Behind The Recent Rally seekingalpha.com - January 16 at 7:51 AM
	This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst finance.yahoo.com - January 3 at 5:39 PM
	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract finance.yahoo.com - December 20 at 5:58 PM
	Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update technews.tmcnet.com - November 8 at 6:31 PM
	Vaxcyte Has A Bright Future Ahead seekingalpha.com - November 2 at 3:24 PM
	Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week finance.yahoo.com - October 30 at 6:49 PM
	Why Shares of Vaxcyte Rose 110.7% This Week finance.yahoo.com - October 29 at 1:56 PM
	Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares benzinga.com - October 28 at 6:41 PM
	Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares finance.yahoo.com - October 28 at 6:41 PM
	Vaxcyte (PCVX) Has Rallied 70% This Week on Trial Results. Is There More Upside? 247wallst.com - October 26 at 5:21 PM
	Vaxcyte Announces Pricing of $600 Million Public Offering finance.yahoo.com - October 26 at 2:18 AM
	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants finance.yahoo.com - October 25 at 11:03 AM
	Vaccine developer Vaxcyte stock soars on results of experimental pneumonia jab finance.yahoo.com - October 25 at 11:03 AM
	Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why finance.yahoo.com - October 25 at 11:03 AM
	How Is The Market Feeling About Vaxcyte? msn.com - October 24 at 12:49 PM
	Vaxcyte climbs 38% after proof-of-concept data for pneumococcal vaccine seekingalpha.com - October 24 at 12:49 PM
	Bill Gates' Big Vaccine Bet Might Beat Pfizer thestreet.com - October 24 at 12:49 PM
	Vaxcyte Shares Are Soaring: Here's Why markets.businessinsider.com - October 24 at 12:49 PM
	Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults finance.yahoo.com - October 23 at 8:49 PM
	Vaxcyte Expands Executive Leadership Team with Key Appointments finance.yahoo.com - October 11 at 8:32 PM
	Vaxcyte (PCVX) Shares Cross Below 200 DMA nasdaq.com - October 4 at 3:48 PM
	Needham Reaffirms Their Buy Rating on Vaxcyte (PCVX) markets.businessinsider.com - September 28 at 10:47 AM
	Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013 markets.businessinsider.com - September 6 at 6:33 PM
	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older finance.yahoo.com - September 6 at 6:33 PM
	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely finance.yahoo.com - August 15 at 7:09 AM
	Vaxcyte (PCVX) Investor Presentation - Slideshow seekingalpha.com - August 13 at 7:13 PM
	Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update finance.yahoo.com - August 8 at 6:56 PM
	Vaxcyte wins FDA’s Fast Track designation for pneumococcal vaccine candidate seekingalpha.com - August 4 at 1:03 PM
	Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs finance.yahoo.com - August 4 at 1:02 PM
	Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study finance.yahoo.com - July 14 at 2:37 PM
	Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study markets.businessinsider.com - July 12 at 8:39 PM
	Vaxcyte to Present at the Jefferies Healthcare Conference finance.yahoo.com - June 2 at 7:14 PM
	PCVX Makes Bullish Cross Above Critical Moving Average nasdaq.com - May 13 at 3:24 PM
	Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update finance.yahoo.com - May 9 at 6:37 PM
	Could The Vaxcyte, Inc. (NASDAQ:PCVX) Ownership Structure Tell Us Something Useful? finance.yahoo.com - May 4 at 2:33 PM
	Vaxcyte to Participate in Upcoming Investor Conferences in May nz.finance.yahoo.com - May 3 at 9:48 AM
	Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 5 at 1:17 PM
	Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults finance.yahoo.com - April 4 at 11:41 AM
	Companies Like Vaxcyte (NASDAQ:PCVX) Are In A Position To Invest In Growth finance.yahoo.com - March 8 at 8:28 AM
	Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update finance.yahoo.com - February 28 at 5:43 PM
	Vaxcyte doses first patients in phase 1/2 trial of pneumonia vaccine seekingalpha.com - February 24 at 9:22 AM

Get Vaxcyte News Delivered to You Automatically

This page (NASDAQ:PCVX) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vaxcyte - PCVX News Today

PCVX Media Mentions By Week

PCVX Media Sentiment

PCVX News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info